Pathophysiology of Diabetic Dyslipidemia
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
Accumulating clinical evidence has suggested serum triglyceride (TG) is a leading predictor of atherosclerotic cardiovascular disease, comparable to low-density lipoprotein (LDL)-cholesterol (C) in populations with type 2 diabetes, which exceeds the predictive power of hemoglobinA1c. Atherogenic dyslipidemia in diabetes consists of elevated serum concentrations of TG-rich lipoproteins (TRLs), a high prevalence of small dense low-density lipoprotein (LDL), and low concentrations of cholesterol-rich high-density lipoprotein (HDL)2-C. A central lipoprotein abnormality is an increase in large TG-rich very-low-density lipoprotein (VLDL)1, and other lipoprotein abnormalities are metabolically linked to increased TRLs. Insulin critically regulates serum VLDL concentrations by suppressing hepatic VLDL production and stimulating VLDL removal by activation of lipoprotein lipase. It is still debated whether hyperinsulinemia compensatory for insulin resistance is causally associated with the overproduction of VLDL. This review introduces experimental and clinical observations revealing that insulin resistance, but not hyperinsulinemia stimulates hepatic VLDL production. LDL and HDL consist of heterogeneous particles with different size and density. Cholesterol-depleted small dense LDL and cholesterol-rich HDL2 subspecies are particularly affected by insulin resistance and can be named "Metabolic LDL and HDL," respectively. We established the direct assays for quantifying small dense LDL-C and small dense HDL(HDL3)-C, respectively. Subtracting HDL3-C from HDL-C gives HDL2-C. I will explain clinical relevance of measurements of LDL and HDL subspecies determined by our assays. Diabetic kidney disease (DKD) substantially worsens plasma lipid profile thereby potentiated atherogenic risk. Finally, I briefly overview pathophysiology of dyslipidemia associated with DKD, which has not been so much taken up by other review articles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, the activation of PPARα reduces small dense LDL particles by (1) producing apo C-III-poor VLDL particles that interacts less well CETP and (2) increasing the formation of large buoyant LDL that has a high affinity to and are easily taken up by LDL receptor.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Non-elevated LDL cholesterol values together with higher triglycerides and lower HDL-cholesterol are common in patients with abdominal obesity, T2D, and metabolic syndrome (61, 62); these individuals often still have elevated atherogenic lipoproteins such as non-HDL (63), small LDL particles (62, 64), and VLDL (62, 64).”
From Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial (2019) · cites this paper as [64]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cholesterol accumulation in the brain, particularly in astrocytes, contributes to this pathological process.”
From Cholesterol-driven pathological astrocytic responses in diabetes-associated cognitive impairment through astrocytic SCAP accumulation and NF-κB–C3 signaling modulation (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411
Lewis, G. F., Carpentier, A., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,333
Stampfer, M. J. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110036029 · Cited by 1,079
Cited by
Poznyak, A., Grechko, A. V., Poggio, P., Myasoedova, V. A., Alfieri, V., & Orekhov, A. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051835 · Cited by 1,163
“Diabetes-associated dyslipidemia received much attention during recent years and became the subject of numerous review papers [36,37].”
BackgroundJoseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Insulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 385
“The sdLDL-C particles are particularly proatherogenic for various reasons: their smaller size facilitates their entrance into the vessel walls; they have impaired affinity with the LDL-C receptor; a longer half-life and lower resistance to oxidation.(127,128)”
BackgroundAthinarayanan, S. J., Adams, R. N., Hallberg, S. J., McKenzie, A. L., Bhanpuri, N. H., Campbell, W. W., Volek, J. S., Phinney, S. D., & McCarter, J. P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00348 · Cited by 324
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Tuleta, I., & Frangogiannis, N. G. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166044 · Cited by 208
“Hypertriglyceridemia and low HDL are the most common serum lipid abnormalities observed in diabetic patients [127].”
BackgroundYamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191
Hong, H., Xu, Y., Xu, J., Zhang, J., Xi, Y., Pi, H., Yang, L., Yu, Z., Wu, Q., Meng, Z., et al. (2021) · Environment International · doi:10.1016/j.envint.2021.106406 · Cited by 172
Efferocytosis in atherosclerosis
Adkar, S. S., & Leeper, N. J. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01037-7 · Cited by 193
“For example, chronic hyperglycaemia drives metabolic syndrome and hyperlipidaemia, which causes atherosclerosis 205–207 .”
Ubiquitin-Specific Proteases (USPs) and Metabolic Disorders
Kitamura, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043219 · Cited by 155
“Western diets increase LDL cholesterol levels and decrease high-density lipoprotein (HDL) cholesterol levels in the blood [206].”
BackgroundTuleta, I., & Frangogiannis, N. G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113904 · Cited by 150
Renal Lipid Metabolism and Lipotoxicity in Diabetes
Thongnak, L., Pongchaidecha, A., & Lungkaphin, A. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.11.004 · Cited by 133
Liu, Y., Zhong, X., Shen, J., Jiao, L., Tong, J., Zhao, W., Du, K., Gong, S., Liu, M., & Wei, M. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146554 · Cited by 129
Shared pathways for neuroprogression and somatoprogression in neuropsychiatric disorders
Morris, G., Puri, B. K., Walker, A. J., Maes, M. H. J., Carvalho, A. F., Bortolasci, C. C., Walder, K. R., & Berk, M. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.09.025 · Cited by 125
Rehman, K., Haider, K., Jabeen, K., & Akash, M. S. H. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09549-6 · Cited by 123
Singh, A. K., Rana, H. K., Singh, V. K., Yadav, T. C., Varadwaj, P. K., & Pandey, A. K. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104462 · Cited by 102
Atherogenic dyslipidemia and diabetic nephropathy
Russo, G. T., Piscitelli, P. A., Giandalia, A., Viazzi, F. C., Pontremoli, R., Fioretto, P., & Cosmo, S. D. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00739-8 · Cited by 95
Romeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 108
“93,94 A decrease in LPL activity further contributes to increased triglyceride levels.”
Akt: A Potential Drug Target for Metabolic Syndrome
Miao, R., Fang, X., Wei, J., Wu, H., Wang, X., & Tian, J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.822333 · Cited by 100
“The main features of dyslipidemia are high plasma triglyceride (TG) levels, decreased high-density cholesterol (HDL) levels, and increased low-density lipoprotein (LDL) levels (Hirano, 2018).”
BackgroundHorton, W. B., Love, K. M., Gregory, J. M., Liu, Z., & Barrett, E. J. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00826.2024 · Cited by 104
The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases
Bernardi, S., Marcuzzi, A., Piscianz, E., Tommasini, A., & Fabris, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124058 · Cited by 76
“With respect to diabetes, given that insulin stimulates LPL activity and inhibits hormone-sensitive lipase in the adipose tissue, circulating chylomicrons increase as well as the amount of FFA that are released by the adipose tissue, which facilitate hepatic VLDL production [148].”
BackgroundUSP2-Related Cellular Signaling and Consequent Pathophysiological Outcomes
Kitamura, H., & Hashimoto, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031209 · Cited by 79
“The liver is also a primary organ for lipid metabolism; it synthesizes cholesterol from triglycerides and releases cholesterol into the circulatory system [107].”
BackgroundThe roles of dietary lipids and lipidomics in gut-brain axis in type 2 diabetes mellitus
Ağagündüz, D., İçer, M. A., Yeşildemir, Ö., Koçak, T., Koçyiğit, E., & Capasso, R. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04088-5 · Cited by 89
“The decreased VLDL catabolism is impacted by rising apoC3 serum levels and their impact on LPL metabolism [131].”
BackgroundEffect of low-carbohydrate diets on cardiometabolic risk, insulin resistance, and metabolic syndrome
O’Neill, B. J. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000569 · Cited by 78
“Similarly, high-triglycerides-rich HDL is hydrolyzed by lipoprotein lipase, resulting in smaller HDL particles which are more rapidly removed from the circulation [16,38–40].”
BackgroundInfluentialLipid Disorders and Metabolic-Associated Fatty Liver Disease
Anwar, S. D., Foster, C., & Ashraf, A. P. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.01.003 · Cited by 77
Lipid metabolism disorder in diabetic kidney disease
Han, Y.-Z., Du, B., Zhu, X., Wang, Y., Zheng, H., & Liu, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1336402 · Cited by 85
Zhang, C., Zhou, B.-G., Sheng, J., Chen, Y., Cao, Y.-Q., & Chen, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104984 · Cited by 72
Colantoni, A., Bucci, T., Cocomello, N., Angelico, F., Ettorre, E., Pastori, D., Lip, G. Y. H., Ben, M. D., & Baratta, F. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02263-6 · Cited by 69
Antidiabetic potential of soy protein/peptide: A therapeutic insight
Das, D., Kabir, M. E., Sarkar, S., Wann, S. B., Kalita, J., & Manna, P. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.11.131 · Cited by 62
Rong, Q., Han, B., Li, Y., Yin, H., Li, J., & Hou, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.729384 · Cited by 70
“In patients with diabetic nephropathy, the albumin concentration in urine is higher, and the filtration of albumin-bound fatty acids is increased, further aggravating renal tubular cell damage (Stadler et al., 2015; Hirano, 2018).”
BackgroundHaile, K., & Timerga, A. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s283171 · Cited by 57
“Elevated free fatty acids can directly disrupt the activity of lipoprotein lipase by causing it to detach from the endothelial surface.(12,13) Consequently, the increased hepatic availability of free fatty acids leads to decreased degradation of apoB, thus causing an overproduction of very-low-density lipoprotein in i…”
Mechchate, H., Es-safi, I., Conte, R., Hano, C., Amaghnouje, A., Jawhari, F. Z., Radouane, N., Bencheikh, N., Grafov, A., & Bousta, D. (2021) · Nutrients · doi:10.3390/nu13082759 · Cited by 65
“A misfunction of insulin can have a direct impact on lipid metabolism, resulting in hypertriglyceridemia and hypercholesterolemia [40], increasing the secretion of LDL and causing a decrease in HDL levels [41].”
BackgroundA-FABP in Metabolic Diseases and the Therapeutic Implications: An Update
Li, H., Wu, X., Xu, A., & Hoo, R. L. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179386 · Cited by 60
“The mechanism through which dyslipidemia develops is closely related to insulin resistance [88], as unrestrained lipolysis leads to an increased hepatic flux of FFA, contributing to increased hepatic TG, hence VLDL production [89,90].”
BackgroundSanz‐París, A., Matía-Martín, P., Martín-Palmero, Á., Gómez‐Candela, C., & Robles, M. C. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.02.036 · Cited by 55
Plasma Amino Acids Metabolomics' Important in Glucose Management in Type 2 Diabetes
Alqudah, A. M., Wedyan, M. A., Qnais, E. Y., Jawarneh, H., & McClements, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.695418 · Cited by 54
“Moreover, LDL and TGs were found to be significantly increased in people with T2D which is consistent with several previously published studies and also associated with the increased risk of cardiovascular complications (Khan, Sobki and Khan, 2007; Hirano, 2018).”
ResultNaseri, K., Saadati, S., Yari, Z., Asbaghi, O., Hezaveh, Z. S., Mafi, D., Hoseinian, P., Ashtary‐Larky, D., Hekmatdoost, A., & de Courten, B. V. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106288 · Cited by 59
Paublini, H., López‐González, Á. A., Busquets-Cortés, C., Tomás-Gil, P., Sbert, P. R., & Ramírez‐Manent, J. I. (2023) · Nutrients · doi:10.3390/nu15092105 · Cited by 56
“When VLDL leaves the liver, it exchanges triglycerides for esterified cholesterol with the other lipoproteins (HDL and LDL), thus becoming triglyceride-rich lipoproteins, which increases their atherogenic power [9]; alteration in the lipid profile favours the accelerated development of atherosclerosis [10],”
BackgroundWang, C., Zhang, C., Li, S., Yu, L., Tian, F., Zhao, J., Zhang, H., Chen, W., & Zhai, Q. (2020) · Foods · doi:10.3390/foods9111540 · Cited by 48
“In addition, the nature of LDL particles in patients with diabetes is more atherogenic than in those patients who are nondiabetic [46].”
BackgroundSekimoto, T., Koba, S., Mori, H., Sakai, R., Arai, T., Yokota, Y., Sato, S., Tanaka, H., Masaki, R., Oishi, Y., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.60152 · Cited by 48
Park, J., Kim, D. H., Lee, H., Hwang, I., Yoon, Y. E., Park, H. E., Choi, S., Kim, Y.-J., Cho, G., Han, K., et al. (2020) · Circulation Research · doi:10.1161/circresaha.119.315705 · Cited by 52
Govindarajan, S., Babu, S. N., Vijayalakshmi, M. A., Manohar, P., & Noor, A. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114556 · Cited by 53
Lu, Q., Chen, J., Jiang, L., Geng, T., Tian, S., Liao, Y., YANG, K. Y., Zheng, Y., He, M., Tang, H., et al. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.08.023 · Cited by 47
de Souza, D. R., Pieri, B. L. D. S., Comin, V. H., Marques, S. D. O., Luciano, T. F., Rodrigues, M. S., & de Souza, C. T. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107553 · Cited by 48
Dhondge, R. H., Agrawal, S., Patil, R., Kadu, A., & Kothari, M. (2024) · Cureus · doi:10.7759/cureus.67428 · Cited by 60
Active Wavefront Correction in Laser Interferometric Gravitational Wave Detectors
Lawrence, R. (2003) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 55
Wang, H., Huang, X., Xu, P., Liu, X., Zhou, Z., Wang, F., Li, J., Wang, Y., Xian, X., Liu, C., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154740 · Cited by 43
Hazem, R. M., Ibrahim, A. Z., Ali, D. A., & Moustafa, Y. M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108503 · Cited by 44
Kalra, S., & Raizada, N. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.11.002 · Cited by 73
(−)-Epicatechin and the comorbidities of obesity
Cremonini, E., Iglesias, D. E., Kang, J., Lombardo, G. E., Mostofinejad, Z., Wang, Z., Zhu, W., & Oteiza, P. I. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108505 · Cited by 44
Hirano, T., Satoh, N., Kodera, R., Hirashima, T., Suzuki, N., Aoki, E., Oshima, T., Hosoya, M., Fujita, M., Hayashi, T., et al. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13697 · Cited by 44
“TC (mg/dL) 182 (31) 182 (29) 181 (34) 174 (45) ns HDL-C (mg/dL) 54 (14) 55 (14) 53 (14) 46 (10) 0.”
Self-citationNorwitz, N. G., Soto-Mota, A., Kaplan, B., Ludwig, D. S., Budoff, M. J., Kontush, A., & Feldman, D. (2022) · Metabolites · doi:10.3390/metabo12050460 · Cited by 48
“TG-rich HDLs are also prone to hepatic lipase-mediated lipolysis [45] (activity of hepatic lipase is also elevated in atherogenic dyslipidemia [46,47]) and ultimately accelerated HDL clearance by the liver and kidneys, further depleting HDL [45,48–52].”
ResultInfluentialLipid Disorders in NAFLD and Chronic Kidney Disease
Yang, M., Geng, C., Liu, X., & Guan, M. (2021) · Biomedicines · doi:10.3390/biomedicines9101405 · Cited by 46
“VLDL exchanges TG with the cholesterol contained in circulating low-density lipoprotein (LDL) and high-density lipoprotein (HDL), resulting in the formation of small LDL (sLDL) and reduced level of small HDL cholesterol (HDL-C) particles [84].”
BackgroundOuchi, G., Komiya, I., Taira, S., Wakugami, T., & Ohya, Y. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-021-01612-8 · Cited by 48
“VLDL1, after the action of cholesteryl ester transfer protein, produces cholesterol-poor LDL particles (sdLDL) via hydrolysis of TGs by hepatic TG lipase.”
BackgroundInfluentialLee, J., Lee, H. S., Cho, A., Lee, Y., & Kwon, Y. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.01.016 · Cited by 41
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
“Those sdLDL specifically arise from large and TG-rich subpopulation of VLDL1 particles, which are predominant in diabetes [5,96].”
BackgroundLi, J., Nie, Z., Ge, Z., Shi, L., Gao, B., & Yang, Y. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01691-1 · Cited by 44
“The increase of triglyceride-rich lipoproteins generally correlates to a reduction in high-density lipoproteins and an addition in lowdensity lipoproteins [14, 15].”
BackgroundHsu, S.-H., Syu, D.-K., Chen, Y., Liu, C., Sun, C., & Chen, M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19137804 · Cited by 39
“These mechanisms are linked to insulin resistance and hyperglycemia, which resulted in the overproduction of TG-rich lipoproteins from the liver [70].”
BackgroundRisk Factors for Progression of CKD with and without Diabetes
Zhang, X., Fang, Y., Zou, Z., Hong, P., Zhuo, Y., Xu, Y., & Wan, J. (2022) · Journal of Diabetes Research · doi:10.1155/2022/9613062 · Cited by 40
“Increased LDL was found to be a risk factor for CKD progression only in CKD patients with diabetes, indicating that diabetes patients are more prone to having glucose and lipid metabolism disorders [15], and it is necessary to strengthen the monitoring and intervention of dyslipidemia to help delay the progression of…”
BackgroundObesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges
Tsilingiris, D., Vallianou, N. G., Spyrou, N., Kounatidis, D. C., Christodoulatos, G. S., Karampela, Ι., & Dalamaga, Μ. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00542-z · Cited by 50
“Of note, this pattern is consistent with the so-called diabetic dyslipidemia, which likely emerges as a result of insulin resistance and increased production of large buoyant VLDL1 particles by the liver [164, 165].”
BackgroundLipid abnormality in diabetic kidney disease and potential treatment advancements
Tu, Q. M., Jin, H. M., & Yang, X. H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1503711 · Cited by 37
Hypertriglyceridemia-Related Pancreatitis In Patients With Type 2 Diabetes: Links And Risks
Shemesh, E., & Zafrir, B. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s188856 · Cited by 45
“The advances in the understanding of the pathophysiology of diabetic dyslipidemia are summarized in recent reviews.(61,67) Yet, the pathophysiologic basis of diabetic dyslipidemia is still not completely understood and requires further research.”
BackgroundAbdissa, D., & Hirpa, D. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02489-w · Cited by 42
Mo, Z., Zhan, M., Yang, X., Xie, P., Xiao, J., Cao, Y., Xiao, H., & Song, M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132251 · Cited by 44
Luty, R. S., Al-Zubaidy, A. A., Malik, A. S., Salman, H., & Abbas, A. H. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03949-8 · Cited by 42
“It is also thought that dyslipidemia, i.e., high TG and low HDL-C levels, is an independent risk factor for the development and progression of DKD, being partly responsible for its residual risk once glucose and blood pressure control are achieved (Hirano 2018).”
Lipoprotein Subfractions and Glucose Homeostasis in Prediabetes and Diabetes in Taiwan
Hsu, H., Hsu, P.-W., Cheng, M., Ito, Y., Kanda, E., Schaefer, E. J., & Ai, M. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48330 · Cited by 37
Type 2 diabetes – unmet need, unresolved pathogenesis, mTORC1-centric paradigm
Bar‐Tana, J. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09545-w · Cited by 43
Ullah, H., Filippis, A. D., Khan, H. Z., Xiao, J., & Daglia, M. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111574 · Cited by 36
Pancreas–Liver–Adipose Axis: Target of Environmental Cadmium Exposure Linked to Metabolic Diseases
Moroni-González, D., Sarmiento-Ortega, V. E., Díaz, A., Brambila, E., & Treviño, S. (2023) · Toxics · doi:10.3390/toxics11030223 · Cited by 35
“VLDL1 is a TRL, and its formation is highly dependent on hepatic triglyceride accumulation (cytosolic lipid droplets) and FFA fluxes from serum to the liver [161,162].”
BackgroundHigh-Density Lipoprotein Alterations in Type 2 Diabetes and Obesity
Denimal, D., Monier, S., Bouillet, B., Vergès, B. L., & Duvillard, L. (2023) · Metabolites · doi:10.3390/metabo13020253 · Cited by 44
“Typically, the dyslipidemia observed in insulin-resistant states is characterized by an elevated triglyceride (TG) level, the predominance of small, dense, low-density lipoproteins (LDLs), and a low high-density lipoprotein cholesterol (HDL-C) level [7].”
BackgroundHyassat, D., Al-Saeksaek, S., Naji, D., Mahasneh, A., Khader, Y. S., Abujbara, M. A., El‐khateeb, M., & Ajlouni, K. M. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1002466 · Cited by 41
“Metabolic syndrome with its associated insulin resistance leads to increased lipolysis by reducing inhibition of hormone-sensitive lipase in adipose tissue, thereby stimulating portal flux of free fatty acids to the liver (5, 6).”
BackgroundRecent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases
Huang, W., Chen, Y., Li, Z., He, F., & Zhang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810882 · Cited by 33
“Hyperlipidemia is another risk factor for DKD progression, especially increases in triglycerides, low-density lipoprotein cholesterol (LDL-C), and apolipoprotein-B-100, which may increase the incidence of cardiovascular events in patients with DM with persistent albuminuria [35].”
BackgroundLoesch, D. P., Garg, M., Matelska, D., Vitsios, D., Jiang, X., Ritchie, S. C., Sun, B. B., Runz, H., Whelan, C. D., Holman, R. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56695-z · Cited by 40
“…of proteins, the directions of the effect of the T2D T2D_gw and a comorbidity PGS on circulating levels were opposite (e.g., the effect of PGS T2D_gw and PGS CKD on MANSC4 levels, see Supplementary Data 8), possibly indicating more complicated relationships such as compensatory responses 21,24 .”
Srivastava, R. A. K. (2018) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-018-0378-y · Cited by 33
Hirano, T. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.14398 · Cited by 40
“Insulin resistance is a central mechanism for abnormal lipoprotein metabolism in T2D and metabolic syndrome 80 , and is closely related to elevated sdLDL-C levels 81,82 .”
Self-citationPathophysiology and emerging biomarkers of cardiovascular-renal-hepato-metabolic syndrome
Nzobokela, J., Muchaili, L., Mwambungu, A., Masenga, S. K., & Kirabo, A. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1661563 · Cited by 44
“Insulin resistance impairs lipoprotein lipase activity, reducing peripheral lipid clearance, while hepatic overproduction of VLDL leads to an accumulation of triglyceride-rich lipoproteins in circulation (54).”
Sundararajan, S., Jayachandran, I., Subramanian, S. C., Anjana, R. M., Balasubramanyam, M., Mohan, V., Venkatesan, B. A., & Manickam, N. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01429-9 · Cited by 33
Triglycerides and endothelial function: molecular biology to clinical perspective
Kajikawa, M., & Higashi, Y. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000630 · Cited by 33
“Overproduction of VLDL1 particles promotes the generation of sdLDL particles and reduces HDL-C levels, leading to endothelial dysfunction [43].”
BackgroundPrediction of Metabolic Disorders Using NMR-Based Metabolomics: The Shanghai Changfeng Study
Wu, Q., Huang, Q., Zeng, H., Ma, S., Lin, H., Xia, M., Tang, H., & Gao, X. (2021) · Phenomics · doi:10.1007/s43657-021-00021-2 · Cited by 30
“While in a state of hepatic insulin resistance, the serum VLDL concentration would increase by stimulating VLDL assembly, enlarging the VLDL particle size, increasing VLDL secretion, and decreasing VLDL catabolism (Hirano 2018).”
BackgroundThambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 51
“Other regulators of LPL include ApoAV and angiopoietin-like proteins (ANGPTLs) but the role of IR in affecting these molecules to increase TG-rich lipoprotein (TRL) catabolism remains to be elucidated [23].”
BackgroundInfluentialDiabetic dyslipidemia: evaluation and mechanism
Yanai, H., Hirowatari, Y., & Yoshida, H. (2019) · Global Health & Medicine · doi:10.35772/ghm.2019.01007 · Cited by 32
“(32) suggesting a significant influence of visceral obesity on VLDL (29,30).”
BackgroundWu, T., Chou, C., Cheng, C.-F., Lu, S.-X., & Wang, L. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.10.005 · Cited by 35
Endocrine diseases as causes of secondary hyperlipidemia
Bułdak, Ł., Marek, B., Kajdaniuk, D., Urbanek, A., Janyga, S., Bołdys, A., Basiak, M., Maligłówka, M., & Okopień, B. (2019) · Endokrynologia Polska · doi:10.5603/ep.a2019.0041 · Cited by 29
“What is more, due to alterations in lipid transfer by CETP, LDL cholesterol particles in those patients become very atherogenic — “small dense LDLs” [16].”
BackgroundKumari, R., Negi, M., Thakur, P., Mahajan, H., Raina, K., Sharma, R., Singh, R., Anand, V., Ming, L. C., Goh, K. W., et al. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02694-0 · Cited by 28
“Insulin resistance, a hallmark of type 2 diabetes, plays a pivotal role in the development of these lipid abnormalities; diabetic dyslipidemia significantly enhances the risk of cardiovascular diseases in diabetic individuals (Hirano 2018).”
Lv, Y., Zhao, P., Pang, K., Ma, Y., Huang, H., Zhou, T., & Yang, X. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113654 · Cited by 31
Cai, X., Ji, L., Liu, S., Wang, M., Heizhati, M., & Li, N. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s304994 · Cited by 29
“Excess adipose tissue releases many lipid metabolites, pro-inflammatory cytokines and cellular stress, all of which mediate insulin resistance.(67,68) FPG level can reflect the secretion level and function of basal insulin.”
BackgroundJavrushyan, H., Nadiryan, E., Grigoryan, A., Avtandilyan, N. V., & Maloyan, A. (2022) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2022.104763 · Cited by 30
Qi, Y., Liu, J., Wang, W., Wang, M., Zhao, F., Sun, J., Liu, J., Deng, Q., & Zhao, D. H. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.49841 · Cited by 28
Eryngium Species as a Potential Ally for Treating Metabolic Syndrome and Diabetes
Pérez-Muñoz, E. P., Antunes‐Ricardo, M., Ávila, M. M., & Guajardo‐Flores, D. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.878306 · Cited by 28
“Dyslipidemia is related to the activities of atherogenic lipoproteins and antiatherogenic, high-density lipoprotein C (HDL-C), which involves the increase of triglycerides, low-density lipoprotein (LDL), and lipoproteins (15).”
BackgroundChang, R., Liu, J., Ji, F., Fu, L., Xu, K., Yang, Y., & Ma, A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129812 · Cited by 26
Hirano, T., & Ito, Y. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63865 · Cited by 29
“ΔsdLDL-C 0 (14) 5 (5) -4 (11)** 4 (12) 14 (9) -5 (11)*** 2 (13) 15 (10) -5 (11)***”
Self-citationHirano, T., Kodera, R., Hirashima, T., Suzuki, N., Aoki, E., Hosoya, M., Oshima, T., Hayashi, T., Koba, S., Ohta, M., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.62789 · Cited by 31
Self-citationSharahili, A. Y., Mir, S. A., Aldosari, S., Manzar, M. D., Alshehri, B., Othaim, A. A., Alghofaili, F., Madkhali, Y., Albenasy, K. S., & Alotaibi, J. S. (2023) · Diseases · doi:10.3390/diseases11040154 · Cited by 25
“Atherogenic dyslipidemia is characterized by high triglyceride (TG) levels, low high-density lipoprotein (HDL) levels, and high low-density lipoprotein (LDL) levels in serum [13].”
BackgroundYamada, H., Yoshida, M., Funazaki, S., Morimoto, J., Tonezawa, S., Takahashi, A., Nagashima, S., Masahiko, K., Kiyoshi, O., & Hara, K. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10040176 · Cited by 28
“Insulin resistance causes postprandial dyslipidemia and contributes to the development of atherosclerosis (diabetic dyslipidemia) [40].”
BackgroundVelagapudi, S., Karsai, G., Karsai, M., Mohammed, S. A., Montecucco, F., Liberale, L., Lee, H., Carbone, F., Adami, G. F., Yang, K., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae100 · Cited by 24
Significance of Lipid Profile Parameters in Predicting Pre-Diabetes.
Jasim, O. H., Mahmood, M. M., & Ad'hiah, A. H. (2022) · PubMed · doi:10.22092/ari.2021.356465.1846 · Cited by 38
Regulation of serine palmitoyl-transferase and Rac1–Nox2 signaling in diabetic retinopathy
Alka, K., Mohammad, G., & Kowluru, R. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-20243-2 · Cited by 23
Prnová, M. Š., Kováčiková, L., Švík, K., Bezek, Š., Elmazoğlu, Z., Karasu, Ç., & Štefek, M. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01769-1 · Cited by 23
“Considering the notion that the main source of hypertriglyceridemia in this type 2model of diabetes is increased hepatic production of triglycerides (Hirano 2018; Adeli et al. 2001), this finding indicates that cemtirestat may not interfere with the processes involved, namely with the enhanced flux…”
BackgroundPoledniczek, M., Neumayer, C., Kopp, C. W., Schlager, O., Gremmel, T., Józkowicz, A., Gschwandtner, M. E., Koppensteiner, R., & Wadowski, P. P. (2023) · Biomedicines · doi:10.3390/biomedicines11082284 · Cited by 29
“First, DMassociated dyslipidaemia leads to increased triglyceride-rich lipoproteins (TLP) in serum [75].”
Doke, M., Komagamine, Y., Kanazawa, M., Iwaki, M., Suzuki, H., Miyazaki, Y., Mizuno, T., Okayasu, K., & Minakuchi, S. (2021) · BMC Oral Health · doi:10.1186/s12903-020-01373-3 · Cited by 27
“In a state of diabetic dyslipidemia, insulin resistance is strongly correlated with elevated TG levels, which would increase serum HDL and LDL, and cause abnormalities in glucose metabolism [11].”
BackgroundEstimated insulin sensitivity in Type 1 diabetes adults using clinical and research biomarkers
Januszewski, A. S., Sachithanandan, N., Ward, G., Karschimkus, C. S., O'Neal, D. N., & Jenkins, A. J. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108359 · Cited by 24
Metadata
- Authors
- Hirano, T.
- Affiliations
- SHOWA Medical University (JP)
- Corresponding author
- Hirano, Tsutomu
- ORCID
- Hirano, Tsutomu
- Venue
- Journal of Atherosclerosis and Thrombosis
- Publisher
- Japan Atherosclerosis Society
- Published
- 2018-09-01
- Volume
- 25
- Issue
- 9
- Pages
- 771-782
- ISSN
- 1340-3478 (ISSN-L)
- 1880-3873
- PMC
- PMC6143775
- OpenAlex
- W2820707192
- Cited by
- 552
- References
- 102
- Citations by year
- 2026: 65 · 2025: 90 · 2024: 81 · 2023: 86 · 2022: 88 · 2021: 70 · 2020: 46 · 2019: 21 · 2018: 4
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Journal of Atherosclerosis and Thrombosis (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- diabetic dyslipidemia, type 2 diabetes, triglyceride-rich lipoproteins, VLDL, small dense LDL, HDL2, HDL3 cholesterol, insulin resistance, hyperinsulinemia, lipoprotein lipase, atherosclerotic cardiovascular disease, diabetic nephropathy, plasma lipid profile
- MeSH terms
- Pioglitazone, Animals, Cholesterol, Chylomicrons, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Fatty Acids, Nonesterified, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Lipoproteins, Cholesterol, HDL, Cholesterol, LDL, Lipoproteins, VLDL, Liver, Risk, Triglycerides, Cholesterol, VLDL, Dyslipidemias, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.